Dr. Kenneth Kornman to Discuss Periodontal Inflammation and
WALTHAM, Mass., June 3 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (Amex: ILI), announced today that Dr. Kenneth Kornman, Chief Scientific Officer, will present at the 13th International Conference on Periodontal Research (ICPR) on June 6, 2008 in Ljubljana, Slovenia on the genetic and environmental factors that control inflammation differences among individuals. The ICPR meeting has been held approximately every three years since 1969 to bring together the world's leaders in periodontal research to reassess the current knowledge in the field and to identify new research direction, to improve the diagnosis, prevention, and treatment of periodontal diseases.
Periodontitis is a bacterially-induced chronic inflammatory disease
that causes destruction of bone and other tissues that support the teeth.
Severe periodontitis, that usually leads to loss of multiple teeth, is
found in approximately 8-13 percent of the adult population. The presence
and severity of periodontitis have been associated with an increased risk
for other important inflammatory conditions, including pre-term births,
cardiovascular disease, rheumatoid arthritis, and certain cancers.
WHO: Dr. Kenneth Kornman, Chief Scientific Officer of Interleukin
WHERE: 13th International Conference on Periodontal Research (ICPR) in
WHEN: Friday, June 6, 2008 at 9:45-10:30 GMT
WHAT: Approximately 30-60 percent of the severity of periodontal disease
is determined by genetics. Interleukin Genetics developed and
markets the PST(R) genetic test to help identify individuals at
increased risk for severe periodontal disease and complications
from dental implants. This test helps dentists guide the
management of their patients' periodontal disease to avoid
complications of severe periodontitis.
About Interleukin Genetics
Interleukin Genetics, Inc. (Amex: ILI) is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin is headquartered in Waltham, MA. For more information about Interleukin, its products and ongoing programs, please visit http://www.ilgenetics.com.
Certain statements contained herein are "forward-looking" statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns and our ability to make progress in advancing our core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the risk of market acceptance of our products, the risk of technology and product obsolescence, delays in product development, the performance of our commercial partners, the availability of adequate capital, the actions of our competitors and other competitive risks, and those risks and uncertainties described in our annual reports on Form 10-K, our quarterly reports on Form 10-Q and other documents we file with, or furnish to, the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.
|SOURCE Interleukin Genetics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved